Keywords: GW Pharmaceutical, cannabinoid medicine, Sativex, Great Point Partners

New GW Pharma Shares Issued Raising $11.2m

Article | 06 August 2009

Print This

GW Pharmaceutical, the UK developer and manufacturer of a range of new cannabinoid medicines, including Sativex, has signed an agreement ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in